Estrogen receptor mutations and changes in estrogen receptor and progesterone receptor protein expression in metastatic or recurrent breast cancer

Japanese Journal of Cancer Research

Volumn 89, Issue 1, 1998, Pages 27-32

  Umekita, Yoshihisa ^a   Sagara, Yoshiatsu ^b   Yoshida, Hiroki ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b Saguru Hospital   (Japan)

Author keywords

Estrogen receptor; Metastasis; Mutation

Indexed keywords

ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; PROGESTERONE RECEPTOR; RECEPTOR ANTIBODY;

ARTICLE; BINDING SITE; BREAST CANCER; CANCER GROWTH; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATION RATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR GENE; RECURRENT CANCER;

EID: 0031936094     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1998.tb00475.x     Document Type: Article

References (20)

1. Clark, G. M. and McGuire, W. L. Steroid receptors and other prognostic factors in primary breast cancer. Semin. Oncol., 15, 20-25 (1988).
2. Rubens, R. D. and Hayward, J. L. Estrogen receptors and responses to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer. Cancer, 46, 2924-2992 (1980).
3. Karnik, P. S., Kulkarni, S., Liu, X. P., Budd, T. and Bukowski, R. M. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res., 54, 349-353 (1994).
4. Roddi, N., Bailey, L. R., Kao, W. Y., Verrier, C. S., Yee, C. J., Dupont, W. D. and Parl, F. F. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J. Natl. Cancer Inst., 87, 446-451 (1995).
5. Taplin, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N. and Balk, S. P. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med., 332, 1393-1398 (1995).
6. Zhang, Q. X., Borg, A., Wolf, D. M., Oesterreich, S. and Fuqua, S. A. W. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res., 57, 1244-1249 (1997).
7. Brunn, R. B. and Kamby, C. Immunohistochemical detection of estrogen receptors in paraffin sections from primary and metastatic breast cancer. Pathol. Res. Pract., 185, 856-859 (1989).
8. Toi, M., Hamada, Y., Seto, Y., Tanimoto, M., Nakamura, T., Toge, T., Niimoto, M. and Hattori, T. Immunocytochemical study on the variation in estrogen receptors of primary and nodal metastases of breast cancer. Jpn. J. Surg., 18, 228-231 (1988).
9. Andersen, J. and Poulsen, H. S. Relationship between estrogen receptor status in the primary tumor and its regional and distant metastases. An immunohistochemical study in human breast cancer. Acta Oncol., 27, 761-765 (1988).
10. Johnston, S. R. D., Saccani-Jotti, G., Smith, I. E., Salter, J., Newby, J., Coppen, M., Ebbs, S. R. and Dowsett, M. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Rex., 55, 3331-3338 (1995).
11. World Health Organization. "Histological Typing of Breast Tumors," 2nd Ed., pp. 18-19 (1981). WHO, Geneva.
12. Umekita, Y., Kobayashi, K., Saheki, T. and Yoshida, H. Nuclear accumulation of p53 protein correlates with mutations in the p53 gene on archival paraffin-embedded tissues of human breast cancer. Jpn. J. Cancer Res., 85, 825-830 (1994).
13. Ponglikitmongkol, M., Green, S. and Chambon, P. Genomic organization of the human oestrogen receptor gene. EMBO J., 7, 3385-3388 (1988).
14. Pertschuk, L. P., Feldman, J. G., Kim, Y. D., Braithwaite, L., Schneider, F., Braverman, A. S. and Axiotis, C. Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222 Spγ in frozen sections or cytosol-based ligand-binding assays. Cancer, 77, 2514-2519 (1996).
15. Zhang, Q. X., Hilsenbeck, S., Fuqua, S. A. W. and Borg, A. Multiple splicing variants of the estrogen receptor are present in individual breast tumors. J. Steroid Biochem. Mol. Biol., 59, 251-260 (1996).
16. McGuire, W. L., Chamness, G. C., Fuqua, S. A. W. Estrogen receptor variants in clinical breast cancer. Mol. Endocrinol., 5, 1571-1577 (1991).
17. Al Saati, T., Clamens, S., Cohen-Knafo, E., Faye, J. C., Prats, H., Coindre, J. M., Wafflart, J., Caveriviere, P., Bayard, F. and Delsol, G. Production of monoclonal antibodies to human estrogen-receptor protein (ER) using recombinant ER (RER). Int. J. Cancer, 55, 651-654 (1993).
18. Smith, E. P., Boyd, J., Frank, G. R., Takahashi, H., Cohen, R. M., Specker, B., Williams, T. C., Lubahn, D. B. and Korach, K. S. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med., 331, 1056-1061 (1994).
19. Fisher, B., Redmond, C., Brown, A., Wickerham, D. L., Wolmark, N., Allegra, J., Escher, G., Lippman, M., Savlov, E. and Wittliff, J. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J. Clin. Oncol., 1, 227-241 (1983).
20. Catherine, W. H., Wolf, D. M. and Jordan, V.C. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. Mol. Endocrinol., 9, 1053-1063 (1995).